Keywords: aphton, g17dt, shows, promise, gastric, cancer, interim
Aphton's G17DT shows promise in gastric cancer
Article | 18 February 2002
Interim results of a Phase II study of Aphton's immunogen G17DT incombination with chemotherapy (cisplatin plus 5-fluorouracil and leucovorin) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
